Glaukos (GKOS) Q2 2026 Earnings Call Transcript

Glaukos reported record Q2 net sales of $185.6M, up 50% YoY (49% constant currency), led by U.S. glaucoma sales of $118.5M (+64% YoY) with iDose TR generating ~$74M. Management raised FY2026 net sales guidance to $680M–$700M (from $620M–$635M) and expects non-GAAP gross margin of ~85% vs 83% prior year, while targeting operating expenses of ~ $600M. Launch traction for Epioxa continued (about $11M in its first full commercial quarter) alongside favorable Medicare coverage progress via iDose LCD discussions, though the company flagged potential Q3 volatility from the J-code transition and some international reimbursement headwinds.

Analysis

This is less a one-quarter beat than a proof point that the business is entering a mix-led inflection: the highest-quality revenue is now coming from reimbursed, procedure-based therapies that can compound without proportional SG&A growth. That matters because it improves the equity story from "good launch" to "self-funding platform," which is the path to multiple expansion in medtech when investors believe gross margin can stay structurally elevated and R&D can be funded internally.

The next catalyst is not demand, it is reimbursement plumbing. Over the next 4-8 weeks, the shares will trade on how quickly claims, prior auths, and payer behavior normalize under the new billing code; over 1-3 months, the key question is whether the launch broadens beyond early adopters or stalls in a few dense centers. A restrictive coverage outcome would hit sentiment immediately, even if it only delays revenue recognition rather than destroying long-term demand.

Contrarian view: bulls may be underestimating how much of the upside is already a 2027 story, while bears may be overestimating the fragility of the launches. If the installed base converts and Medicare Advantage/commercial access keeps widening, the addressable market can expand faster than consensus models assume; if not, this remains a nice growth story with a heavy dependence on policy execution. The clean falsifier is a deeper-than-expected Q3 air pocket in corneal health or any materially adverse final coverage language on iDose.

Key Decisions for Investors

• Initiate a starter long in GKOS now, but only size it for a 3-6 month catalyst window; add on any 5-8% post-earnings pullback as the better entry than chasing strength.
• Use a defined-risk bullish structure in GKOS if options liquidity is acceptable: medium-dated call spreads into the next reimbursement catalyst, since upside should be driven by payer normalization while downside is capped by the balance sheet.
• Do not press the long until early July/August claims data confirms the permanent billing code is translating into repeatable approvals; if the first post-code data shows a steep drop in conversion, the thesis weakens quickly.
• Set a hard watch item on any final LCD language or coverage revision for iDose; if that turns materially restrictive, cut the position and treat the launch as delayed rather than accelerated.